ARVO 2018: Port Delivery System Designed to Reduce Burden of Lucentis Injections for Wet AMD
Research News
Dr. Christopher Brittain, Genentech medical director, discusses his company’s port delivery system, a tiny capsule implanted into the eye, for delivery of Lucentis® over a period of a few months.
Dr. Christopher Brittain, Genentech medical director, discusses his company's port delivery system, a tiny capsule implanted into the eye, for delivery of Lucentis® over a period of a few months. The device is currently in a Phase 2 clinical trial. The image on the right shows the port implanted into an eye.
